Results 181 to 190 of about 340,736 (281)

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference. [PDF]

Europace
Svennberg E, Merino JL, Andrade J, Anselmino M, Arbelo E, Boersma E, Boriani G, Breithardt G, Chung M, Chyou J, Cohen A, Nielsen JC, Dichtl W, Diederichsen SZ, Dobrev D, Doehner W, Dworatzek E, Fabritz L, Filgueiras-Rama D, Gimpelewicz C, Hack G, Hatem S, Healey J, Heidbuchel H, Hijazi Z, Holst AG, Hove-Madsen L, Jalife J, van Leerdam R, Linz D, Lip GYH, Lubitz S, de Melis M, Meyer R, Orczykowski M, Parwani AS, Porta-Sanchez A, de Potter T, Ravens U, Rienstra M, Rillig A, Rivard L, Scherr D, Schnabel RB, Schotten U, Simovic S, Sinner M, Sohns C, Sommer P, Steinbeck G, Steven D, Sultan A, Thomalla G, Toennis T, Tzeis S, Voigt N, Wadhwa M, Wakili R, Witt H, Goette A, Kirchhof P.   +60 more
europepmc   +1 more source

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet   +5 more
wiley   +1 more source

Clinical Trials on Atrial Fibrillation in Asia: Where Are We Now. [PDF]

JACC Asia
Kong X, Yang Z, Ma C.
europepmc   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source

Prognostic role of TAPSE to PASP ratio in outpatients with left ventricular systolic dysfunction

ESC Heart Failure, Volume 12, Issue 2, Page 912-922, April 2025.
Abstract Aims Few data are available regarding the role of tricuspid annulus plane systolic excursion to pulmonary artery systolic pressure (TAPSE/PASP), a measurement of right ventricular to pulmonary artery coupling, in patients with chronic heart failure and left ventricular systolic dysfunction.
Mauro Riccardi, Matteo Pagnesi, Rossana Corso, Antonio M. Sammartino, Daniela Tomasoni, Riccardo M. Inciardi, Carlo M. Lombardi, Marianna Adamo, Savina Nodari, Marco Metra   +9 more
wiley   +1 more source

Advanced Interatrial Block Predicts New Onset Atrial Fibrillation in Patients with Severe Heart Failure and Cardiac Resynchronization Therapy

, 2015
Fariha Sadiq Ali, Andrés Enríquez, Diego Conde, Damian Redfearn, Kevin Michael, Christopher S. Simpson, Hoshiar Abdollah, Antoni Bayés de Luna, Wilma M. Hopman, Adrián Baranchuk   +9 more
openalex   +2 more sources

The Global Impact of Atrial Fibrillation. [PDF]

Arrhythm Electrophysiol Rev
Karatela MF, Calkins H.
europepmc   +1 more source

Association of BMI with adherence and outcome in heart failure patients treated with wearable cardioverter defibrillator

ESC Heart Failure, Volume 12, Issue 2, Page 1295-1303, April 2025.
Abstract Background Obesity is a known risk factor for cardiovascular disease (CVD), yet an ‘obesity paradox’ has been observed in various CVD contexts. The impact of obesity on heart failure (HF) patients treated with a wearable cardioverter‐defibrillator (WCD) remains underexplored.
Mohammad Abumayyaleh, Katharina Koepsel, Julia W. Erath, Thomas Kuntz, Norbert Klein, Boldizsar Kovacs, Firat Duru, Ardan M. Saguner, Christian Blockhaus, Dong‐In Shin, Fabienne Kreimer, Michael Gotzmann, Hendrik Lapp, Thomas Beiert, Assem Aweimer, Andreas Mügge, Christel Weiß, Ibrahim El‐Battrawy, Ibrahim Akin   +18 more
wiley   +1 more source

Balancing clinical responsibilities and research during electrophysiology fellowship

HeartRhythm Case Reports
Panteleimon E. Papakonstantinou, MD, MSc, PhD, FESC
doaj   +1 more source